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PolymorphismNon-alcoholic fatty liver disease (NAFLD) is now recognised as the most common cause of liver dysfunction
worldwide. However, whilst the majority of individuals who exhibit features of the metabolic syndrome
including obesity and insulin resistancewill develop steatosis, only aminority progress to steatohepatitis,ﬁbrosis
and cirrhosis. Subtle inter-patient genetic variations and environment interact to determine disease phenotype
and inﬂuence progression. A decade after the sequencing of the human genome, the comprehensive study of
genomic variation offers new insights into the modiﬁer genes, pathogenic mechanisms and is beginning to
suggest novel therapeutic targets.Wereviewthe current statusof theﬁeldwithparticular focus onadvances from
recent genome-wide association studies.y Ofﬁce, The Medical School,
e-upon-Tyne, NE2 4HH, UK.
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Non-alcoholic fatty liver disease (NAFLD) represents a spectrum
of liver disease encompassing simple fatty inﬁltration of the liver
parenchyma (steatosis), fat and inﬂammation (non-alcoholic steato-
hepatitis; NASH) and cirrhosis, in the absence of excessive alcohol
consumption (typically a threshold of b20 g/day for women and
b30 g/day for men is adopted) [1,2]. Population studies show that
NAFLD is strongly associated with obesity, insulin resistance/type II
diabetes mellitus and dyslipidaemia and it is considered by many to
be the hepatic manifestation of the metabolic syndrome [3–5]. It is
now recognised that NAFLD is the most common cause of liver
dysfunction in developed countries [1]. Estimates vary between
populations however one large European study found NAFLD present
in 94% of obese patients (BMI N30 kg/m2), 67% of overweight patients
(BMI N25 kg/m2), and 25% of normal weight patients [6]. The overall
prevalence of NAFLD in type 2 diabetics ranges from 40% to 70% [6]. As
only a minority of patients with NAFLD progress to more advanced
disease characterised by inﬂammation, ﬁbrosis, cirrhosis and hepato-
cellular carcinoma (HCC), NAFLD is best considered a complex disease
trait where subtle inter-patient genetic variations and environment
interact to determine disease phenotype and progression [7,8].
Here we will review the current understanding of genetic modiﬁers
of NAFLD/NASH with particular focus on data from human studies
(Fig. 1).2. Pathogenesis
Our current understanding of disease pathogenesis has been
achieved through clinic based research and the translational study of
speciﬁc animal models [9,10]. The initiating events in NAFLD/NASH
relate to the development of obesity and insulin resistance. Together,
these promote hepatic free fatty acid (FFA) ﬂux which provides the
appropriatemilieu for NAFLD/NASH to develop. Importantly, the visible
steatosis that has for some time been considered the ‘ﬁrst hit’ in the
pathogenesis of NAFLD/NASH is now recognised by many investigators
to beanepiphenomenon reﬂecting these changes inhepatocyte FFAﬂux
and associated cellular stress responses. Recognition of this means that
steatosis should now be considered an early adaptive response to
hepatocyte stress through which potentially lipotoxic FFAs are parti-
tioned into relatively stable intracellular triglyceride stores. This was
elegantly demonstrated by silencing of hepaticDGAT2 expression, a key
enzyme mediating the conversion of FFA to triglyceride [11]. Rather
than ameliorating steatohepatitis, the consequent reduction in hepato-
cyte triglyceride synthesis was associated with a greater level of fatty
acid oxidation, particularly throughCyp2E1, leading to greater oxidative
stress, cellular damage and higher serum transaminase levels [11].
Discussion of pathogenesis and the genetic modiﬁers of progressive
NAFLD should now consider the combined effects of several fundamen-
tal biochemical and immunological mechanisms of liver injury rather
than adhering to a sequential ‘two-hit’ paradigm. These effects include:
(1) Direct hepatocyte lipotoxicity; (2) Hepatocellular oxidative stress
secondary to free radicals produced during β- and ω-FFA oxidation;
(3) Endotoxin/TLR4 induced Kupffer cell cytokine release; (4) Cytokine
release; and (5) Endoplasmic reticulum (ER) stress. Consequent cellular
damage triggers a mixture of immune mediated hepatocellular injury
and both necrotic and apoptotic cell death pathways [12–14]. If these
Fig. 1. Summary of genetic modiﬁers of progressive NAFLD.
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collagen deposition and hepatic ﬁbrosis [15]. In depth discussion of
these mechanisms falls outside the scope of this review, however this
framework will be adopted in our discussion of genetic modiﬁers.
3. Techniques for investigating the genetic basis of NAFLD/NASH
Until recently, the primary approach to the genetic study of
complex disease traits was through case–control disease-association
studies in man where candidate genes were selected on the basis of a
putative role of their encoded proteins in disease pathogenesis. Being
reliant on an a priori hypotheses for gene selection, these studies were
limited to known candidates and therefore were not able to explore
the potential role of other less obvious genes that may have an equal
or greater inﬂuence on disease susceptibility.
In the ten years since the publication of the draft human genome
there have been signiﬁcant advances in our understanding of genomic
variation. Several million single nucleotide polymorphisms (SNPs)
have been described across individuals from diverse ethnic back-
grounds [16–18]. This has paved the way for the development of SNP
genotyping arrays and genome-wide association studies (GWAS) that
have allowed the majority of common (minor allele frequency N5%)
variability in the human genome to be simultaneously surveyed. The
availability of high throughput next-generation sequencing offers the
prospect of even more comprehensive characterisation of genomic
variability, particularly the more rare genetic variants that are not
effectively identiﬁed by GWAS but which may have a relatively large
effect on disease risk. Greater discussion of these techniques falls
outside the scope of this review but they are discussed more fully
elsewhere [19–21].
The utility of the GWAS approach was demonstrated by one of the
earliest reports describing simultaneous study of seven differentcomplex diseases [22]. Since then, the number of GWAS studies in the
literature has expanded exponentially. Amongst these, several liver-
related diseases and traits have been studied. Factors that inﬂuence
variation in biochemical liver function tests [23], drug induced liver
injury [24,25], gallstone disease [26], primary biliary cirrhosis [27–29],
NAFLD [30–32], hepatitis B persistence [33] and hepatitis C treatment
response [34,35] have been identiﬁed. Awelcome consequence ofwider
adoption of non-hypothesis driven GWAS techniques is that the loci
identiﬁed are frequently novel and would not previously have been
implicated in disease pathogenesis. However, as often neither biological
function nor pathogenic mechanisms are known, such associations
require further detailed study both to determine activity and to validate
causality. In addition, candidate gene association studies have examined
modiﬁers of disease progression and ﬁbrosis [36,37].
4. Genome wide association studies in NAFLD/NASH research
To date, three GWAS scale studies have been reported in this ﬁeld
[30–32]. Each has captured new data and provided additional insights
into the role of genomic variation in NASH pathogenesis (Table 1).
4.1. The ﬁrst GWAS — Romeo et al.
The ﬁrst NASH related GWAS was a genome-wide survey of non-
synonymous sequence variation encompassing 9229 SNPs across a
mixed population of Hispanic, African American and European
ancestry derived from the Dallas Heart Study [30,38]. Although not
based on direct assessment of steatosis in liver biopsy samples, the
non-invasive proton magnetic resonance spectroscopy (1H-MRS)
technique used to assess hepatic steatosis is widely adopted in both
human and murine studies [39,40]. The striking results of this study
clearly identiﬁed the patatin-like phospholipase domain-containing 3
Table 1
Loci identiﬁed in NAFLD/NASH GWAS studies.
Study SNP Gene symbol Gene name/location Association
Romeo, 2008 [30] rs738409 PNPLA3 Patatin-like phospholipase domain-containing 3 MRI measured steatosis
Chalasani, 2010 [31] rs2645424 FDFT1 Farnesyl diphosphate farnesyl transferase 1 Histological NASH activity score
rs343062 - Chromosome 7 Histological ﬁbrosis
rs1227756 COL13A1 Collagen, type XIII, alpha 1 Histological lobular inﬂammation
rs6591182 - Chromosome 11 Histological lobular inﬂammation
rs887304 EFCAB4B EF-hand calcium binding domain 4B Histological lobular inﬂammation
rs2499604 - Chromosome 1 Serum ALT
rs6487679 PZP Pregnancy zone protein Serum ALT
rs14212001 - Chromosome 18 Serum ALT
rs2710833 - Chromosome 4 Serum ALT
Speliotes, 2011 [32] rs738408 PNPLA3 Patatin-like phospholipase domain-containing 3 CT measured steatosis and histological NAFLD
rs2228603 NCAN Neurocan CT measured steatosis and histological NAFLD
rs4240624 PPP1R3B Protein phosphatase 1, regulatory (inhibitor) subunit 3B CT measured steatosis (not validated in histology cohort)
rs780094 GCKR; Glucokinase regulator Histological NAFLD
rs12137855 LYPLAL1 Lysophospholipase-like 1 Histological NAFLD
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NASH pathogenesis. The study demonstrated that the PNPLA3 I148M
variant, induced by a cytosine to guanine nucleotide transversion
mutation (SNP rs738409) which results in an isoleucine to methio-
nine amino acid change at codon 148, was associated with increased
hepatic fat burden (p=5.9×10−10) [30]. The variant allele was most
common in Hispanics (minor allele frequency 0.49), which is the
group most susceptible to NAFLD and where carriage was also found
to be associated with increased ALT and AST levels. Minor allele
frequency was lower in people of European descent (0.23) and lowest
in African–Americans (0.17), the group found to have the lowest
levels of hepatic triglyceride accumulation. Furthermore, a gene
dosage effect was observed with heterozygote carriage of the I148M
minor allele conferring increased hepatic triglyceride content over
wild-type and homozygotes having even greater levels (2-fold more
than non-carriers). The same study also reported a second sequence
variation in PNPLA3 (rs6006460) causing a serine to isoleucine change
in codon 453 (S453I). In contrast to the I148M variation, S453I had the
opposite ethnic distribution and was associated with reduced hepatic
triglyceride levels [30,41]. Together, these two variants were able to
account for 72% of the ethnic variation in steatosis observed in the
study population.
4.2. The second GWAS — Chalasani et al.
A second NAFLD GWAS, which was not limited to non-
synonymous genetic variation, has recently been reported [31].
This used a relatively small all-female cohort of 236 biopsy-
conﬁrmed NAFLD patients and involved genotyping for 325,000
SNPs. Following adjustment for age, BMI, diabetes, waist:hip ratio
and HbA1c levels in multivariate analysis, an association was
identiﬁed between severity of histological NAFLD activity score
and SNP rs2645424 on chromosome 8 in the gene encoding farnesyl
diphosphate farnesyl transferase 1 (FDFT1) (p=6.8×10−7), an
enzyme with a role in cholesterol biosynthesis. Other associations
with ﬁbrosis (chromosome 7, rs343062; p=2.7×10−8) and lobular
inﬂammation were seen (including an SNP in the collagen gene
COL13A1 (p=2.0×10−7)). In addition loci associatedwith raise ALT
were also identiﬁed. No associations with steatosis, ballooning
degeneration or portal inﬂammation were identiﬁed and it is
perhaps surprising that no association for any feature of NAFLD
with PNPLA3was seen in this study.Whilst the associations detected
in this study are potentially interesting, they remain to be
independently replicated in larger patient cohorts. A recent study
in a UK cohort of 340 NAFLD patients failed to ﬁnd any association
for the FDFT1 rs2645424 SNP with severity of either ﬁbrosis or
steatosis [42].4.3. The third GWAS — Speliotes et al.
The most recent large-scale study of genetic variation in NAFLD
adopted a two-stage approach [32]. In a ﬁrst exploratory stage,
computerised tomography (CT) measurement of hepatic steatosis
was examined in a meta-analysis of GWAS data across individuals
drawn from several large population studies (Age/Gene/Environment
Susceptibility-Reykjavik Study, Old Order Amish Study, Family Heart
Study and Framingham Heart Study). Genotypes for 2.4 million SNPs
in over 7100 individuals were available. SNPs from 45 loci associated
with hepatic lipid content (pb10−3) were identiﬁed and association
validity tested using a cohort of 592 patients with biopsy proven
NASH derived from the NIH NASH CRN cohort. Five SNPs associated
with aspects of the NAFLD phenotype in or near the genes PNPLA3
(rs738408), neurocan (NCAN; rs2228603), protein phosphatase 1,
regulatory (inhibitor) subunit 3B (PPP1R3B; rs4240624), glucokinase
regulator (GCKR; rs780094) and lysophospholipase-like 1 (LYPLAL1;
rs12137855) were identiﬁed. The rs738408 PNPLA3 SNP is in strong
linkage disequilibrium with the rs738409 SNP previously identiﬁed
[30]. PNPLA3, NCAN and PPP1R3B were most strongly associated with
CT measured steatosis at pb5×10−8 in the initial study. This was also
conﬁrmed in the histology validation study for PNPLA3 and NCAN but
not PPP1R3B. Two additional SNPs in or near GCKR and LYPLAL1 were
shown to be associated with histological steatosis. NCAN, GCKR,
LYPLAL1 and PNPLA3 were associated with histologically assessed
lobular inﬂammation and/or ﬁbrosis. In addition, variants in or near
NCAN, GCKR and PPP1R3B were associated with altered serum lipid
levels and variants near GCKR and PPP1R3B affected glycemic traits.
This large study conﬁrmed the strong association for PNPLA3 rs738408
with steatosis shown in the ﬁrst GWAS study (Section 4.1) and by
candidate gene association studies (see Section 5.2.1 below). The
other associations are novel though not as strong as for PNPLA3.
LYPLAL1 codes for a protein with a complementary function to the
PNPLA3 gene product in triglyceride breakdown so the observed
association is biologically plausible. The NCAN gene product may have
a role in cell adhesion whereas GCKR codes for a regulator of glucose
metabolism and both are therefore interesting genes in terms of
NAFLD susceptibility though further studies are needed to identify the
precise causative SNPs and the underlying mechanisms affecting
disease severity.
5. Genetic modiﬁers of NAFLD pathogenesis and progression
5.1. Genetic modiﬁers of metabolic syndrome risk
When considering genetic modiﬁers of NAFLD one should ﬁrst
consider those genes that inﬂuence aetiological factors causally linked
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insulin resistance and obesity for NAFLD. Rather than being simple
environmental challenges, these factors are themselves, at least in
part, genetically determined.
5.1.1. Obesity
In terms of obesity related genes [43], initial candidate studies
were based on discoveries from mutant mouse models and focussed
on genes related to leptin signalling which links obesity with NAFLD
[9,44,45], however the effect of these genes has proved to be
uncommon in human disease [46]. Identiﬁcation of the FTO gene by
GWAS analysis of a cohort of obese patients has provided a new
candidate [47]. Translational validation by several groups using
targeted and random mutagenesis techniques has provided exciting
insights into pathogenic mechanisms, however no direct association
with fatty liver has yet been described [48,49]. The role of epigenetic
imprinting as an inﬂuence on obesity and fatty liver phenotypes has
also been explored in models of NAFLD [50].
5.1.2. Insulin resistance
The relationship between insulin resistance and progression of
NAFLD is complex. Whilst multiple loci from GWAS have been
associated with type 2 diabetes and insulin resistance [51], few have
so far carried through to NAFLD. To date, the polymorphisms in
ENPP1/PC-1 (ectoenzyme nucleotide pyrophosphate phosphodiester-
ase 1), and IRS-1 (insulin receptor substrate-1) have been studied in
candidate gene studies. A large study involving 702 pooled biopsy-
proven NAFLD cases from Italy and the UK found that the SNPs in both
ENPP1 (K121Q) and IRS-1 (Q972R) were independently associated
with ﬁbrosis scores N1 and insulin resistance [52]. However, a second
smaller and arguably underpowered study on ENPP1 did not ﬁnd a
signiﬁcant effect on ﬁbrosis [53].
The adiponectin gene may also be relevant to insulin resistance
and the metabolic syndrome more generally and has been well
studied in relation to type 2 diabetes. A study of 119 patients with
NAFLD showed that homozygosity for the variant form of an SNP at
position 45 of exon 2 of this gene was a risk factor for severe ﬁbrosis
but not for NASH [54]. A more recent large Finnish study with two
separate validation cohorts examined the association of polymor-
phisms within adiponectin receptors 1 and 2 (ADIPOR1 and ADIPOR2)
as well as three peroxisome proliferator activated receptors (PPARA,
PPARD and PPARG) with 1H-MRS measured steatosis and concluded
that only the ADIPOR2 SNP (rs767870) was associated with hepatic fat
accumulation [55]. In a Chinese population, an association with the
C161T PPARG SNP, reduced plasma adiponectin levels and NAFLD has
been described. No association was found with the Gly482Ser SNP in
the related protein PPARGC1A [56].
5.2. Genetic modiﬁers of hepatic fatty acid ﬂux and triglyceride levels
Steatosis occurs when the rate of import or synthesis of fatty acids
by hepatocytes exceeds the rate of export or catabolism [57,58]. Given
the recent evidence that esteriﬁcation of FFA to triglyceride is a
protective mechanism which limits hepatocellular exposure to FFA
induced lipotoxicity [11], polymorphisms in genes that mediate
synthesis, storage and export of triglyceride are likely candidate
modiﬁers for NASH severity and progression. The majority of NAFLD
associated genes so far identiﬁed are from traditional candidate gene
allele-association studies based on existing understanding of hepato-
cyte lipid handling.
5.2.1. Patatin-like phospholipase domain-containing 3 (PNPLA3)
As already discussed, interest in the role of PNPLA3 in the
pathogenesis of NASH started with its identiﬁcation as a genetic
modiﬁer of steatosis risk in a GWAS study. Later the same year a
GWAS seeking factors that inﬂuence variation of common clinicalchemistry indices reported that the I148M allele was one of two loci
associated with raised serum ALT levels in populations of European
and Indian–Asian descent (chromosome 10: APN1-ERLIN1-CHUK and
chromosome 2: PNPLA3-SAMM50) [23]. The association of PNPLA3
with NAFLD/NASH has been independently replicated in both adult
[59–62] and paediatric [62–65] cohorts, as has its association with
raised ALT/AST levels [66] (Table 2). There is also evidence from
biopsy based studies that carriers of the I148M variant exhibit more
severe steatohepatitis with greater levels of ﬁbrosis [60,62]. Illustrat-
ing the convergence in our understanding of the pathogenesis of
alcoholic liver disease and NAFLD, studies in alcohol dependent
patients have linked advanced ﬁbrosis or cirrhosis with carriage of the
I148M allele [67]. This has been independently validated in two
additional European cohorts [68,69]. Further, there is evidence that
PNPLA3 inﬂuences steatosis, ﬁbrosis and risk of developing HCC in
patients with chronic hepatitis C infection [70].
The PNPLA3 gene on chromosome 22 encodes a 481 amino acid
protein that is closely related toadipose triglyceride lipase (ATGL/PNPLA2),
the major triglyceride hydrolase in adipose tissue [41,71]. PNPLA3 has
been primarily associated with severity of hepatic lipid accumulation
however its precise physiological role in vivo remains incompletely
characterised [41]. Current evidence would suggest that the inﬂuence of
PNPLA3 on hepatic steatosis is not through affecting insulin resistance as
assessed by hyperinsulinaemic, euglycaemic clamp [59,61] and plasma
insulin response to oral glucose tolerance testing [72]; orwith thebroader
features of themetabolic syndrome such as BMI, dyslipidaemia and overt
type 2 diabetesmellitus [73]. Rather, consistentwith the concept of NASH
as a complex disease trait, the evidence suggests that PNPLA3 variation
sensitises the liver to environmental stressors. Thus, in European cohorts
I148M carriage was only found to associate with elevations of AST/ALT in
the presence of obesity [72].
The challenge remains to better understand the role of PNPLA3 and
hence the mechanisms through which the I148M variant exhibits its
metabolic effects. Studies have to some extent been hampered by
inter-species differences in gene expression pattern. In man PNPLA3 is
found in adipose tissue but is most strongly expressed in the liver
[74,75], whilst in normal mice gene expression is at low levels in liver
tissue but is abundant in white and brown adipose tissue [76,77]. In
both species hepatic expression is increased after feeding and is also
raised in obese humans [59] and in Ob mice [77] whilst fasting
reduces PNPLA3 expression [41,77]. Recent in vitro studies with
recombinant adiponutrin expressed in HUH-7 cells have shown that
this enzyme can hydrolyze emulsiﬁed triglyceride and that the I148M
polymorphism is associated with substantially reduced enzymatic
activity [78]. Structural analysis of PNPLA3 indicates that the I148M
mutation does not directly alter the enzyme's highly conserved
S47/D166 catalytic dyad. Instead, the I148M amino acid change lies
within the hydrophobic substrate-binding groove and prevents
substrate access to the active site [78]. Mechanistic studies demon-
strate that postprandial PNPLA3 expression is controlled by an insulin
mediated feed-forward loop through the LXR/RXR heterodimer and
the transcription factor SREBP-1c [74]. These effects are responsive to
post-translational control by the types of fatty acids present [74].
Speciﬁcally, selected saturated (palmitate, C16:0), monounsaturated
(oleate, C18:1) and polyunsaturated fatty acids (linoleic acid, C18:2)
led to increased PNPLA3 protein expression whilst very long chain
fatty acids (arachadonic acid, C20:4 and eicosapentanoic acid, C20:5)
did not effect PNPLA3 expression [74]. It has also been suggested that,
in addition to lipolytic activity, PNPLA3 may also exhibits lipogenic
transacetylase activity although this has not been uniformly replicat-
ed [78,79]. These apparent mixed enzymatic actions, coupled with the
transcriptional regulation of PNPLA3 by feeding and the speciﬁc fatty
acid proﬁle present suggests that the action of PNPLA3 could vary
according tissue and metabolic milieu. Whilst partially puriﬁed
PNPLA3 can catalyse triglyceride hydrolysis in vitro, expression
patterns and regulation have led some investigators to suggest that
Table 2
Genetic studies indicating a role for PNPLA3 in NAFLD.
Study Study design Cohort studied Associated phenotype
Yuan, 2008 [23] GWAS
(n=12,419)
Indian–Asian and European ↑ ALT (serum biochemistry only)
Romeo, 2008 [30] GWAS
(n=2111)
USA based European–American;
African–American and Hispanic
↑ 1H-MRS liver TG content;
↑ ALT/AST in Hispanics
Kotronen, 2009 [59] Candidate gene
(n=291)
Finnish ↑ 1H-MRS Liver TG content;
No association with insulin resistance
Sookoian, 2009 [60] Candidate gene
(n=266)
Argentinean ↑ Biopsy proven steatosis;
↑ Risk of histological progression and inﬂammation
Kantartzis, 2009 [61] Candidate gene
(n=330)
German ↑ 1H-MRS liver TG content;
↑ ALT and ↑ AST
Romeo, 2010 [72] Candidate gene
(n=678)
Italian (BMIN30 kg/m2) ↑ ALT if obese
Kollerits, 2010 [66] Candidate gene
(n=4290)
European ↑ ALT and ↑ AST
Romeo, 2010 [63] Candidate gene
(n=475)
Italian (obese children/adolescents) ↑ ALT and ↑ AST
Speliotes, 2010 [73] Candidate gene
(n=592)
USA based European–American ↑ Risk of histological progression and inﬂammation
Speliotes, 2011 [32] GWAS Meta-analysis European and USA based cohorts ↑ CT Liver TG content
↑ Risk of histological progression and inﬂammation
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than catabolism [74].
5.2.2. Microsomal triglyceride transfer protein (MTTP)
Microsomal triglyceride transfer protein (MTTP) mediates the
synthesis and secretion of very-low density lipoprotein in the liver
and intestine. A loss of function frame-shift mutation in MTTP causes
abetalipoproteinemia (OMIM #200100) however, whilst this is
associated with marked hepatocyte triglyceride accumulation, it is
much less frequently associated with progressive steatohepatitis or
ﬁbrosis [80]. A guanine to thiamine transversion at position−493 in
the promoter region has been associated with reduced gene
transcription, lowerMTTP levels and hepatocyte failure of triglyceride
excretion. Evidence has been presented that NAFLD patients homo-
zygous for the low-activity G allele have increased steatosis and
higher histological NASH grade compared to heterozygous patients or
patients homozygous for the high-activity T allele [81,82]. Unfortu-
nately, these data should be interpreted with caution as histological
data on NASH activity was only available on a small cohort of 63
patients [81] and a recent larger study of 131 biopsy proven NAFLD
cases from Brazil failed to show a signiﬁcant effect for the same
polymorphism [83].
5.2.3. Phosphatidylethanolamine methyltransferase (PEMT)
Phosphatidylethanolamine methyltransferase (PEMT) catalyses de
novo synthesis of phosphatidylcholine which is needed for very-low-
density lipoprotein synthesis. Two studies have reported an associ-
ation between NAFLD and a non-synonymous PEMT exon 8 guanine-
to-adenine transversion. The larger study included 107 biopsy-proven
NASH patients from Japan and demonstrated that the consequent
loss-of-function V175M amino acid change was more common in
NASH patients compared to controls [84]. Further, V175M positive
NASH patients tended to have lower BMI, suggesting they were
genetically predisposed to develop NASH. A second biopsy-based
American study also suggested that V175M was more common
amongst NASH cases compared to controls [85].
5.2.4. Apolipoprotein C3 (ApoC3)
An association with degree of hepatic steatosis and two SNPs,
rs2854116 (T-455C) and rs2854117 (C-482T), located within the
promoter region of Apolipoprotein C3 (ApoC3) has been reported in
cohorts of Asian-Indian and non-Asian ethnicity [86]. Both SNPs cause
increased ApoC3 expression andwere already recognised asmediators
of postprandial hypertriglyceridaemia in humans and murine studiesvia inhibition of lipoprotein lipase activity. It has been suggested that
the increased circulating chylomicron-remnant load was preferen-
tially taken up by hepatic scavenger receptors leading to steatosis
[86]. However, the association of these SNPs with steatosis severity
was not conﬁrmed in two recent studies. The ﬁrst of these failed to
show any association between these SNPs with either hepatic
triglyceride content or insulin resistance in approximately 2000
Americans of African, European and Hispanic ethnicity [87]. The
second, involving 758 biopsy proven NAFLD cases of European ethnic
origin, failed to show any relationship for these APOC3 SNPs with
steatosis or ﬁbrosis severity or with NASH [88]).
5.2.5. Transcription factors and nuclear receptors
Following the observation that mice deﬁcient in the NR1I2/PXR
(pregnane X receptor) gene develop steatosis [89], a recent study has
focussed on its role in lipid homeostasis and NAFLD. PXR is a
transcription factor with a well established role in regulation of
hepatic detoxiﬁcation mechanisms [90]. It may also inﬂuence lipid
homeostasis through effects on the fatty acid translocase gene (CD36)
and several lipogenic enzymes [89]. Two SNPs (rs7643645 and
rs2461823) were found to be signiﬁcantly associated with aspects
of the NAFLD phenotype in a group of 188 patients comparedwith 102
healthy controls and were also a predictor of disease severity [91].
One SNP (rs7643645) is believed to lie within a binding site for the
transcription factor HNF-4 and so may affect expression of the genes
such as CYP3A4 and ABCB1. Effects on lipid homeostasis are therefore
also possible but the ﬁndings for NAFLD need to be conﬁrmed
independently. SNPs in other genes encoding proteins involved in
regulating intra-hepatic FFA ﬂux and triglyceride synthesis, storage
and export are also attractive candidates as NAFLD risk factors. In
addition to those described above, published candidate gene
association studies support a role for several other genes including
Transcription factor 7-like 2 (TCF7L2) [92], Apolipoprotein E [93,94]
and MRP2 (ABCC2) [95] in hepatic fat accumulation.
5.3. Genetic modiﬁers of progression to steatohepatitis
5.3.1. Genes inﬂuencing oxidative stress
Genetic modiﬁers of oxidative stress fall into two broad categories,
those that encodeproteins involved in thegeneration of reactive oxygen
species (ROS) or those that mediate cellular antioxidant defence. The
formergroup includes genes that are speciﬁc to a given aetiology, aswell
as those that may sensitise hepatocytes to oxidative stress damage
irrespective of aetiology (e.g. HFE). The latter group includes the main
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mutase (SOD2) and genes that inﬂuence the relative abundance of anti-
oxidant reduced glutathione stores.
Given that liver iron deposition promotes oxidative stress, the HFE
gene is an obvious candidate in disease pathogenesis for NAFLD. The
evidence of a role for HFE in NAFLD is mixed. An initial Australian
study demonstrated that 31% of 51 NASH patients carried at least one
copy of the C282Y HFE mutation compared to only 13% of controls
[96]. This is supported by a second study in 126 patients with biopsy
proven NASH which also reported that the C282Y mutation was
associated more advanced disease including bridging ﬁbrosis or
cirrhosis [97]. However, another study of 263 consecutive patients
with NAFLD [98], and two further small European studies [99,100],
found the prevalence of the C282Y and H63Dmutations to be identical
to the control population.
In the face of the increased hepatocyte FFA ﬂux encountered in
NAFLD, mitochondrial β- and extra-mitochondrial β- andω-fatty acid
oxidation are major sources of ROS. An alanine-to-valine substitution
in codon 16 (A16T) of the SOD2 mitochondrial targeting sequence
increases MnSOD activity which leads to increased generation of
peroxide and hence cellular damage. This polymorphism has been
associated with advanced hepatic ﬁbrosis in NAFLD in both Japanese
[81] and European [101] cohorts. The European study used both case–
control and intra-familial association methodology to report a
consistent association between this SNP and ﬁbrosis in NAFLD and
also demonstrated a gene dosage effect where the presence of
signiﬁcant ﬁbrosis increased with the number of valine (T) alleles. In
the family study, the valine allele was transmitted on 47 of 76 possible
occasions (62%), whereas the C allele was transmitted on only 29 of 76
occasions (38%; p=0.038) [101]. Multivariate analysis using a cohort
of more than 500 patients with biopsy proven NASH showed
susceptibility to advanced ﬁbrotic disease was determined by SOD2
genotype (OR 1.56 (95% CI 1.09–2.25), p=0.014), PNPLA3 genotype
(p=0.041), type 2 diabetes mellitus (p=0.009) and histological
severity of NASH (p=2.0×10−16) [101].
Cellular oxidative stress defence is largelymediated by glutathione
whichmay be conjugated to xenobiotics and ROS. Glutamate–cysteine
ligase (gamma-glutamylcysteine synthetase), composed of two sub-
units encoded by the genes GCLC and GCLM, is the rate limiting step in
synthesis of glutathione. Murine studies have demonstrated that
absence of GCLC causes steatosis and liver failure [26]. A recent study
of NAFLD in Brazil involving 131 patients examined the effects of the
C-129T promoter region polymorphism involving the GCLC gene and
demonstrated that carriers of the mutant allele were overrepresented
in a steatohepatitis arm compared to those with simple steatosis [83].
5.3.2. Genes inﬂuencing endotoxin response and TLR4
In recent years there has been mounting interest in the role of the
gut ﬂora–liver axis in the pathogenesis of fatty liver disease with
evidence supporting a role for endotoxin-mediated cytokine release
in the pathogenesis of NAFLD from both human and murine studies.
The identiﬁcation of promoter region polymorphisms in genes
encoding endotoxin receptors has provided investigators with a
new set of candidate genes for study. CD14, a lipopolysaccharide
receptor expressed on monocytes, macrophages and neutrophils
enhances toll-like receptor-4 (TLR4) endotoxin receptor signalling.
Genetic data supporting a role for TLR4 polymorphisms rs4986791
and rs4986790 in the pathogenesis of hepatitis C related ﬁbrosis in
man is available [102,103]. In addition, a spontaneous null mutation in
TLR4 present in C3H/J mice has provided a useful tool with which to
explore the role of TLR4/endotoxin in NAFLD pathogenesis in the
laboratory [104]. One preliminary study in NAFLD found no
association with polymorphisms in either TLR4 or the NOD2 receptor
for bacterial cell wall peptidoglycan but did reported an association
with a cystosine-to-thymine polymorphism at position−159 in the 5’
promoter region of CD14 [105]. Carriage of the CD14 minor allele isassociated with increased expression of both soluble and membrane
bound CD14 [106]. Once again, larger studies are required to validate
these ﬁndings.
5.3.3. Genes inﬂuencing cytokine activity
Investigation of the role of TNFα and other cytokines in NASHwas
ﬁrst stimulated by the apparent similarity between NASH and the
effects of pro-inﬂammatory cytokines such as TNFα [107]. The TNFα
guanine-to-adenine promoter polymorphism at position −238 has
been associated with NASH [108]. In a separate study, DNA from 102
Japanese patients was screened for SNPs in TNFα and serum TNF
receptor-2 levels assayed. sTNFr-2 levels were signiﬁcantly higher in
NASH patients than patients with simple steatosis or healthy
controls. The carrier frequencies of polymorphisms at −1031C and
−863A in the promoter region were signiﬁcantly higher in NASH
than steatosis, however no signiﬁcant difference between those with
NAFLD and the control population was detected [109]. Whilst
interesting, this small study requires replication before any ﬁrm
conclusions on the role of TNFα as a NASH susceptibility gene can be
made. In a small study of 114 NAFLD cases, including 59 who had
undergone liver biopsy, an IL-6 promoter region G-174C SNP was
found to be more common in cases of NASH [53].
5.4. Genetic modiﬁers of ﬁbrogenesis and disease progression
The majority of research into hepatic ﬁbrogenesis has been
conducted in chronic hepatitis C infected cohorts however, as stellate
cell activation and collagen deposition are a ﬁnal common pathway of
chronic liver injury, the genes identiﬁed remain strong candidates for
a role in NAFLD-related ﬁbrosis [110]. Candidates suggested by these
studies include transforming growth factor (TGF)-β1, connective
tissue growth factor, matrix metalloproteinase 3, PPARα, DDX5,
CPT1A and various ﬁbrogenic adipocytokines including angiotensin II.
One of the few pro-ﬁbrotic polymorphisms independently validated
in multiple human viral hepatitis studies and in animal models is
carriage of the pro-coagulant Factor V Leiden mutation (R506Q;
OMIM #612309) [37,111,112]. Given the evidence that the metabolic
syndrome is a pro-coagulant state and that ﬁbrosis progression in
NAFLD is associated with the presence of greater thrombotic risk
[113], it is tempting to speculate that polymorphisms related to
coagulation activation and signalling may also inﬂuence ﬁbrogenesis
[114] however gene association evidence is currently lacking.
The transcription factor nuclear factor-κB (NF)-κB promotes
survival of hepatic myoﬁbroblasts and hepatic ﬁbrogenesis. It is
recognised that angiotensin II mediates this effect through activation
of IκB kinase (IKK) phosphorylation of the NF-κB subunit RelA at Ser
536 [115]. Five of 12 SNPs studied in the angiotensin II receptor 1
(ATGR1) gene were shown to associate with steatohepatitis in a
cohort of patients with biopsy proven NASH [116]. The strongest
association was with SNP rs3772622 (OR=1.95, 95% CI 1.49–2.55;
p=1.2×10−6) with the other four SNPs being found to lie within the
same linkage block. This SNP was also shown to be signiﬁcantly
associated with degree of hepatic ﬁbrosis [116]. Another report
indicates that obese patients possessing both the high TGFβ1 and
angiotensinogen producing SNPs may be more susceptible to
advanced ﬁbrosis. However this study involved very small patient
numbers and is yet to be replicated [117]. These ﬁndings are
consistent with reports that show beneﬁt of angiotensin receptor
blockers such as losartan in ameliorating ﬁbrosing steatohepatitis
both in vitro and in vivo and demonstrate how knowledge of the
genetic modiﬁers of disease may inform development of potential
therapies [115,118].
Kruppel-like factor (KLF6) is a ubiquitously expressed transcrip-
tion factor which was found to be expressed by activated stellate cells
soon after injury [119]. Evidence suggests that KLF6 expression is
increased in rat models of NASH and regulates expression of several
1563Q.M. Anstee et al. / Biochimica et Biophysica Acta 1812 (2011) 1557–1566key genes that mediate ﬁbrogenesis, making it an attractive candidate
modiﬁer of ﬁbrosis severity in human NAFLD [120]. An SNP affecting
mRNA splicing (rs3750861) has been shown to be functionally
signiﬁcant [121]. Carriage of this SNP has been shown to associate
with more mild hepatic ﬁbrosis in three separate European NAFLD
cohorts [36].
6. Conclusions
Like the majority of clinically important diseases, NAFLD is a complex
disease traitwheregenetic factors andenvironmental inﬂuences combine
todeterminediseasephenotypeandprogression. The relative importance
of these factors will vary between populations depending on background
modiﬁer genes and lifestyle choices/challenges. During the last decade
the advent of the GWAS andwhole-genome sequencing technologies has
provided investigatorswith the tools to comprehensively studyvariability
within the human genome. The advent of genome-led tailored therapy
based on genetic risk assessment in the clinic remains some way off.
However, our greater understanding of how genetic variation modiﬁes
disease phenotype offers new insights into the underlying physiological
processes and pathophysiological mechanisms. With this opportunity
comes the challengeof translating theseﬁndings into tangible therapeutic
beneﬁts.
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